Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies

Journal of Clinical Oncology

Volumn 16, Issue 12, 1998, Pages 3866-3873

  Spiridonidis, C ^a   Laufman, Leslie R ^a   Jones, Jacqueline ^a   Rhodes, Virginia A ^a   Wallace, Kelly ^a   Nicol, Steven ^a  

^a Hematology/Oncology Consultants Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG RESPONSE; ERYTHROCYTE TRANSFUSION; ESOPHAGUS CARCINOMA; FEBRILE NEUTROPENIA; FEMALE; FLU LIKE SYNDROME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0032421357     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.12.3866     Document Type: Article

References (32)

1. Guchelaar HJ, Richel DJ, van Knapen A: Clinical, toxicological and pharmacological aspects of gemcitabine. Cancer Treat Rev 222:15-31, 1996
2. Eisenhauer EA: Docetaxel: Current status and future prospects. J Clin Oncol 13:2865-2868, 1995
3. Burkes RL, Shepherd FA: Gemcitabine in the treatment of non-small-cell lung cancer. Ann Oncol 6:57-60, 1995 (suppl 3)
4. Fossella FV, Lee SJ, Murphy WK, et al: Phase II study of docetaxel for recurrent or metastatic, non-small-cell lung cancer. J Clin Oncol 12:1238-1244, 1994
5. Fossella FV, Lee SJ, Shin DM, et al: Phase II study of docetaxel for advanced or metastatic, platinum-refractory non-small-cell lung cancer. J Clin Oncol 13:645-651, 1995
6. Carmichael J, Possinger K, Phillip P, et al: Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 13:2731-2736, 1995
7. Ravdin PM, Burris HA, Cook G, et al: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995
8. Trudeau ME, Eisenhauer EA, Higgins BP, et al: Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14:422-428, 1996
9. Stadler WM, Kuzel T, Roth B, et al: Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15:3394-3398, 1997
10. Pollera CF, Ceribelli A, Crecco M, et al: Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study. Ann Oncol 5:182-184, 1994
11. McCaffrey JA, Hilton S, Mazumdar M, et al: Phase II trial of docetaxel in patients with advanced or metastatic transitional cell carcinoma. J Clin Oncol 15:1853-1857, 1997
12. Francis P, Schneider J, Hann L, et al: Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 12:2301-2308, 1994
13. Shapiro JD, Millward MJ, Rischin D, et al: Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel. Gynecol Oncol 63:89-93, 1996
14. Kaye SB: Gemcitabine: Current status of phase I and II trials. J Clin Oncol 12:1527-1531, 1994
15. Abbruzzesse JL, Grunewald R, Weeks EA, et al: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498, 1991
16. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel: A new highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894, 1995
17. 2 as first-line chemotherapy for patients with advanced breast cancer: Report of the Clinical Screening Group of the EORTC. Br J Cancer 74:650-656, 1996
18. Adachi I, Watanabe T, Takashima S, et al: A late phase II study of RP 56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 73:210-216, 1996
19. Francis PA, Rigas JR, Kris MG, et al: Phase II trial of docetaxel in patients with stage III and stage IV non-small-cell lung cancer. J Clin Oncol 12:1232-1237, 1994
20. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small-cell lung cancer. Cancer 75:968-972, 1995
21. Kunitoh H, Watanabe K, Onoshi T, et al: Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: A Japanese cooperative study. J Clin Oncol 14:1649-1655, 1996
22. Masters GA, Melton K, Brockstein BE, et al: A dose-escalation study of docetaxel with G-CSF in patients with advanced solid tumors: A phase I trial. Proc Am Soc Clin Oncol 17:248a, 1998 (abstr 950)
23. Green S, Weiss G: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239-253, 1992
24. Miller AB, Hoogstrated B, Staquet M: Reporting of cancer treatment. Cancer 47:207-214, 1981
25. Hryniuk WM, Goodyear M: The calculation of received dose-intensity. J Clin Oncol 8:1935-1937, 1990 (editorial)
26. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
27. Pollera CF, Ceribelli A, Crecco M, et al: Weekly gemcitabine in advanced or metastatic solid tumors. A clinical phase I study. Invest New Drugs 12:111-119, 1994
28. Bruno R, Hille D, Riva A, et al: Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187-196, 1998
29. Anderson H, Lund B, Bach F, et al: Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 12:1821-1826, 1994
30. Zalcberg J, Millward M, Bishop J, et al: Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. J Clin Oncol 16:1948-1953, 1998
31. Crino L, Mosconi AM, Scagliotti G, et al: Salvage therapy with gemcitabine in pretreated advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 16: 446a, 1997 (abstr 1603)
32. Gandara DR, Yokes E, Green M, et al: Docetaxel in platinum-pretreated non-small-cell lung cancer: Confirmation of prolonged survival in a multicenter trial. Proc Am Soc Clin Oncol 16:454a: 1997 (abstr 1632)